NBQX disodium saltCAS# 479347-86-9 |
2D Structure
- Limonin
Catalog No.:BCN6057
CAS No.:1180-71-8
- Fosamprenavir Calcium Salt
Catalog No.:BCC1581
CAS No.:226700-81-8
- HIV-1 integrase inhibitor
Catalog No.:BCC1618
CAS No.:544467-07-4
- BMS-626529
Catalog No.:BCC1427
CAS No.:701213-36-7
- HIV-1 integrase inhibitor 2
Catalog No.:BCC1619
CAS No.:957890-42-5
Quality Control & MSDS
3D structure
Package In Stock
Number of papers citing our products
Cas No. | 479347-86-9 | SDF | Download SDF |
PubChem ID | 6098006 | Appearance | Powder |
Formula | C12H6N4O6SNa2 | M.Wt | 380.24 |
Type of Compound | N/A | Storage | Desiccate at -20°C |
Solubility | Soluble to 100 mM in water | ||
Chemical Name | disodium;6-nitro-7-sulfamoylbenzo[f]quinoxaline-2,3-diolate | ||
SMILES | C1=CC2=C3C(=CC(=C2C(=C1)S(=O)(=O)N)[N+](=O)[O-])N=C(C(=N3)[O-])[O-].[Na+].[Na+] | ||
Standard InChIKey | SVJKYIUJRJEABK-UHFFFAOYSA-L | ||
Standard InChI | InChI=1S/C12H8N4O6S.2Na/c13-23(21,22)8-3-1-2-5-9(8)7(16(19)20)4-6-10(5)15-12(18)11(17)14-6;;/h1-4H,(H,14,17)(H,15,18)(H2,13,21,22);;/q;2*+1/p-2 | ||
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. |
Description | Potent, selective and competitive AMPA receptor antagonist. Neuroprotective and anticonvulsant; active in vivo. More water soluble disodium salt of NBQX. Also available as part of the AMPA Receptor. |
NBQX disodium salt Dilution Calculator
NBQX disodium salt Molarity Calculator
1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
1 mM | 2.6299 mL | 13.1496 mL | 26.2992 mL | 52.5984 mL | 65.7479 mL |
5 mM | 0.526 mL | 2.6299 mL | 5.2598 mL | 10.5197 mL | 13.1496 mL |
10 mM | 0.263 mL | 1.315 mL | 2.6299 mL | 5.2598 mL | 6.5748 mL |
50 mM | 0.0526 mL | 0.263 mL | 0.526 mL | 1.052 mL | 1.315 mL |
100 mM | 0.0263 mL | 0.1315 mL | 0.263 mL | 0.526 mL | 0.6575 mL |
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. |
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- CNQX disodium salt
Catalog No.:BCC6908
CAS No.:479347-85-8
- TC OT 39
Catalog No.:BCC7958
CAS No.:479232-57-0
- MMPIP hydrochloride
Catalog No.:BCC7528
CAS No.:479077-02-6
- [Orn8]-Urotensin II
Catalog No.:BCC5793
CAS No.:479065-85-5
- Aucubin
Catalog No.:BCN5355
CAS No.:479-98-1
- Vitexicarpin
Catalog No.:BCN5020
CAS No.:479-91-4
- Artemetin
Catalog No.:BCN5547
CAS No.:479-90-3
- Canthin-6-one
Catalog No.:BCN5546
CAS No.:479-43-6
- Indirubin
Catalog No.:BCN2385
CAS No.:479-41-4
- Cotoin
Catalog No.:BCN5545
CAS No.:479-21-0
- Atranorin
Catalog No.:BCN5544
CAS No.:479-20-9
- Dyphylline
Catalog No.:BCC2297
CAS No.:479-18-5
- AUDA
Catalog No.:BCC4023
CAS No.:479413-70-2
- 1-O-galloyl-2-O-cinnamoyl-beta-d-glucose
Catalog No.:BCC3967
CAS No.:
- CP-809101
Catalog No.:BCC1498
CAS No.:479683-64-2
- Eleutherol
Catalog No.:BCN8480
CAS No.:480-00-2
- Astragalin
Catalog No.:BCN5549
CAS No.:480-10-4
- Oroxylin A
Catalog No.:BCN5363
CAS No.:480-11-5
- Izalpinine
Catalog No.:BCN3682
CAS No.:480-14-8
- Morin
Catalog No.:BCN1028
CAS No.:480-16-0
- Taxifolin
Catalog No.:BCN5550
CAS No.:480-18-2
- Isorhamnetin
Catalog No.:BCN5551
CAS No.:480-19-3
- Aromadendrin
Catalog No.:BCN5552
CAS No.:480-20-6
- Orobol
Catalog No.:BCN5553
CAS No.:480-23-9
Roles of the spinal glutamatergic pathway activated through alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid (AMPA) receptors and its interactions with spinal noradrenergic and serotonergic pathways in the rat urethral continence mechanisms.[Pubmed:24668912]
Neurourol Urodyn. 2015 Jun;34(5):475-81.
AIMS: To investigate the role of the glutamatergic pathway and its relationship to noradrenergic and serotonergic pathways in modulation of the urethral continence reflex during sneezing in rats. METHODS: In female Sprague-Dawley rats under urethane anesthesia, the effects of an alpha-amino-3-hydroxy-5-meth-ylisoxazole-4-propionic acid (AMPA) glutamate receptor antagonist, a norepinephrine reuptake inhibitor and a serotonin [5-hydeoxytripitamine (5-HT)]2B/2C agonist on the amplitude of urethral responses during sneezing (AURS), urethral baseline pressure (UBP), and sneeze-induced leak point pressure (S-LPP) were investigated. RESULTS: Intrathecal application (i.t.) of NBQX disodium salt (an AMPA receptor antagonist) decreased AURS dose-dependently by approximately 60% without affecting UBP and caused stress urinary incontinence (SUI) during sneezing in 60% of normal rats. Nisoxetine (i.t.), a norepinephrine reuptake inhibitor, and mCPP (i.t.), a 5-HT(2B/2C), agonist increased AURS, and NBQX (i.t.) abolished these excitatory effects of nisoxetine (i.t.) and mCPP (i.t.), whereas nisoxetine (i.t.) and mCPP (i.t.) did not enhance AURS in the presence of NBQX (i.t.). CONCLUSION: These results indicate that the glutamatergic pathway acting through AMPA receptors plays a crucial role on the active urethral closure reflex during sneezing at the spinal level, and noradrenergic and serotonergic pathways modulate the reflex via the spinal glutamatergic system in rats.
Antiepileptogenic and anticonvulsant effects of NBQX, a selective AMPA receptor antagonist, in the rat kindling model of epilepsy.[Pubmed:8199874]
Brain Res. 1994 Feb 28;638(1-2):36-44.
To investigate the role of non-NMDA receptors in epileptic seizures, we examined the antiepileptogenic and anticonvulsant effects of NBQX (2,3-dihydroxy-6-nitro-7-sulfamoyl-benzo(F)-quinoxaline), a potent and selective AMPA receptor antagonist, in the rat kindling model. Systemic administration of 10-40 mg/kg NBQX significantly and dose dependently suppressed previously kindled seizures from the amygdala (AM), assessed in terms of the motor seizure stage and afterdischarge (AD) duration. The maximal effects were observed at 0.5-1 h after drug injection. When the intensity of electrical stimulation was increased to twice the generalized seizure-triggering threshold (GST), the anticonvulsant effects of NBQX on AM-kindled seizures were not reversed, suggesting that the effects were not due to non-specific elevation of the GST. In contrast to AM-kindled seizures, 20-40 mg/kg NBQX significantly suppressed only the motor seizure stage without reducing the AD duration of previously hippocampal-kindled seizures. Daily administration of 15 or 30 mg/kg NBQX prior to each electrical stimulation of the AM markedly and significantly suppressed the development of kindling. During drug sessions, the growth of the AD duration was blocked almost completely, while the waveform of ADs became more complex. These results indicate that NBQX has potent antiepileptogenic and anticonvulsant actions on kindling, at least from the AM and that non-NMDA receptors have an important role in seizure propagation.
The neuroprotective actions of 2,3-dihydroxy-6-nitro-7-sulfamoyl-benzo(F)quinoxaline (NBQX) in a rat focal ischaemia model.[Pubmed:1504814]
Brain Res. 1992 May 15;580(1-2):35-43.
The neuroprotective effects of NBQX, a selective antagonist for the AMPA/kainate subtype of excitatory amino acid receptors, were investigated in a rat focal ischaemia model, involving permanent occlusion of the left middle cerebral artery (MCA). NBQX (3, 10 or 30 mg/kg) was administered i.v. immediately after MCA occlusion and again 1 h later. The highest dose of NBQX (2 x 30 mg/kg) gave significant protection against hemispheric (24%) and cortical (27%) ischaemic damage. The lower doses of NBQX (2 x 3 or 2 x 10 mg/kg) were ineffective. No protection was seen against caudate damage for any of the doses of NBQX tested. NBQX has a t1/2 of 30 min, therefore, a second experiment was done in which a dose of 30 mg/kg was given as an i.v. bolus followed immediately by an infusion of 10 mg/kg/h for 4 h, dosing was started immediately after MCA occlusion. This dosing regimen resulted in a mean plasma level over the 4 h of 17 micrograms/ml, and significant protection against the volume of hemispheric (29%) and cortical (35%) ischaemic damage, which was slightly better than that achieved with two bolus doses of 30 mg/kg. Once again no protection was seen against caudate damage. We conclude that NBQX, an AMPA/kainate antagonist was neuroprotective in a focal ischaemia model in the rat.
Pharmacological characterization of non-NMDA subtypes of glutamate receptor in the neonatal rat hemisected spinal cord in vitro.[Pubmed:1382781]
Br J Pharmacol. 1992 Jun;106(2):367-72.
1. A grease-gap technique was used to record depolarizing responses to alpha-amino-3-hydroxy-5-methyl-isoxazole-4-propionate (AMPA), kainate and N-methyl-D-aspartate (NMDA) in the hemisected spinal cord of the neonatal rat. The pharmacology of non-NMDA subtypes of glutamate receptor was investigated with the novel quinoxalinedione, 2,3-dihydroxy-6-nitro-7-sulphamoyl-benzo (F)-quinoxaline (NBQX) and with a series of barbiturates. 2. NBQX antagonized AMPA- and kainate-, but not NMDA- induced depolarizations. The near parallel shifts of the major part of the dose-response curves for AMPA and kainate by NBQX gave pA2 values (+/- s.e.) of 6.7 +/- 0.2 and 6.8 +/- 0.2 respectively, consistent with a common site of action for these two agonists. 3. Below the 50% level at which these pA2 values were calculated, however, an NBQX-resistant plateau was seen within the kainate, but not the AMPA, dose-response curve. 4. In decreasing order of potency, methohexitone, secobarbitone, thiopentone, pentobarbitone and phenobarbitone preferentially reduced kainate-, rather than AMPA- and NMDA-, induced depolarizations. Methohexitone was also the most selective with IC50S against kainate, AMPA and NMDA of 31 +/- 7, 172 +/- 47 and greater than 200 microM respectively. 5. The NBQX-resistant plateau seen within the kainate dose-response curve was reduced by methohexitone. Kainate antagonism by methohexitone was not reduced by 50 microM picrotoxin. 6. We conclude that, while mixed agonist actions may hamper demonstration of antagonist selectivity, depolarizations induced by the non-NMDA ionotropic agonists, AMPA and kainate, are mediated in part via distinct receptors.